Key Highlights

Risk & Performance

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

20%

1 trials in Phase 3/4

Results Transparency

0 of 1 completed trials have results

Key Signals

Phase 2

4(80.0%)

Phase 3

1(20.0%)

5Total

Phase 2(4)

Phase 3(1)

Loading network data...

Showing 5 of 5 trials

Neoadjuvant Response-guided Treatment of Luminal B-type Tumors and Luminal A-type Tumors With Node Metastases

Role: lead

Neoadjuvant Response-guided Treatment of HER2 Positive Breast Cancer

Role: lead

Neoadjuvant Response-guided Treatment of Slowly Proliferating Hormone Receptor Positive Tumors

Role: lead

A Translational Trial on Molecular Markers and Functional Imaging to Predict Response of Preoperative Treatment of Breast Cancer Early

Role: lead

Epirubicin and Paclitaxel, Alone or Together With Capecitabine as First Line Treatment in Metastatic Breast Cancer

Role: lead

All 5 trials loaded